By Digifin Pty Ltd · About this coverage
Key Points
- FDA Type C feedback: HEALEY may support traditional approval and act as single NDA study
- Pathway still subject to substantial evidence of effectiveness and supporting evidence
- Regimen I fully enrolled; topline results expected late Q2 CY2027
- NIH expanded access for about 200 ALS patients expected to start Q1 CY2027
About Neurizon (ASX:NUZ)
Neurizon Therapeutics Limited is an ASX-listed biotechnology company based in Melbourne. It develops treatments for neurodegenerative disease, with lead candidate NUZ-001 in clinical development for amyotrophic lateral sclerosis.
Neurizon (ASX:NUZ) received written FDA Type C meeting responses on NUZ-001's clinical development plan and regulatory pathway in amyotrophic lateral sclerosis. The FDA noted that positive results from the Phase 2/3 HEALEY ALS Platform Trial may support a traditional approval pathway and that the trial may serve as the single registrational study for a New Drug Application, subject to substantial evidence of effectiveness including supporting evidence.
The FDA agreed with measuring plasma neurofilament light chain and outlined evidence needed for NfL to support accelerated approval, while Neurizon's strategy remains focused on traditional approval with biomarker data as supporting evidence. After the January 2026 decision not to grant Fast Track Designation, the FDA advised Neurizon may resubmit an FTD request; the company continues to evaluate that option. HEALEY Regimen I is fully enrolled, with topline results expected in late Q2 CY2027. An NIH-funded expanded access program for about 200 people with ALS for up to 96 weeks is expected to start in Q1 CY2027. The release does not present efficacy results and NUZ-001 remains investigational.
Source: Neurizon Therapeutics Limited (ASX:NUZ), 6 October 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.